2.74 USD
-0.01 (-0.36%)
2.76 USD
+0.02 (+0.73%)
CRON gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. CRON has a great financial health rating, but its profitability evaluates not so good. CRON is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CRON had positive earnings in the past year.
In the past year CRON had a positive cash flow from operations.
CRON had negative earnings in 4 of the past 5 years.
In the past 5 years CRON reported 4 times negative operating cash flow.
1.2 Ratios
CRON has a Return On Assets of 3.06%. This is amongst the best in the industry. CRON outperforms 82.81% of its industry peers.
The Return On Equity of CRON (3.33%) is better than 82.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROIC | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 27.27%, CRON belongs to the top of the industry, outperforming 93.23% of the companies in the same industry.
CRON's Profit Margin has declined in the last couple of years.
With a decent Gross Margin value of 43.35%, CRON is doing good in the industry, outperforming 61.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRON has been increased compared to 1 year ago.
Compared to 5 years ago, CRON has more shares outstanding
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CRON has an Altman-Z score of 8.08. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.08, CRON is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.08 |
ROIC/WACCN/A
WACC8.39%
2.3 Liquidity
A Current Ratio of 22.45 indicates that CRON has no problem at all paying its short term obligations.
CRON's Current ratio of 22.45 is amongst the best of the industry. CRON outperforms 92.19% of its industry peers.
CRON has a Quick Ratio of 21.28. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON has a Quick ratio of 21.28. This is amongst the best in the industry. CRON outperforms 91.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 283.33% over the past year.
Measured over the past years, CRON shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -50.78% on average per year.
The Revenue has grown by 19.00% in the past year. This is quite good.
The Revenue has been growing by 37.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
3.2 Future
CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.39% yearly.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 24.91, the valuation of CRON can be described as rather expensive.
CRON's Price/Earnings ratio is a bit cheaper when compared to the industry. CRON is cheaper than 79.17% of the companies in the same industry.
CRON's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.59.
CRON is valuated quite expensively with a Price/Forward Earnings ratio of 38.38.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRON indicates a somewhat cheap valuation: CRON is cheaper than 70.31% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.03, CRON is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.91 | ||
| Fwd PE | 38.38 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
5. Dividend
5.1 Amount
No dividends for CRON!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.74
-0.01 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.95%
Inst Owner Change5.64%
Ins Owners6.24%
Ins Owner Change0.47%
Market Cap1.05B
Revenue(TTM)132.36M
Net Income(TTM)36.10M
Analysts82.86
Price Target3.73 (36.13%)
Short Float %1.79%
Short Ratio1.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.4%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-5%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)-0.21%
Revenue beat(8)3
Avg Revenue beat(8)-1.43%
Revenue beat(12)4
Avg Revenue beat(12)-1.97%
Revenue beat(16)6
Avg Revenue beat(16)-3.29%
PT rev (1m)110.87%
PT rev (3m)110.87%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-8.28%
Revenue NQ rev (3m)-8.28%
Revenue NY rev (1m)-1.71%
Revenue NY rev (3m)-1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.91 | ||
| Fwd PE | 38.38 | ||
| P/S | 7.93 | ||
| P/FCF | N/A | ||
| P/OCF | 48.23 | ||
| P/B | 0.97 | ||
| P/tB | 1.04 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.11
EY4.01%
EPS(NY)0.07
Fwd EY2.61%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.06
OCFY2.07%
SpS0.35
BVpS2.83
TBVpS2.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% | ||
| FCFM | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 209.86% | ||
| Cap/Sales | 20.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 | ||
| Altman-Z | 8.08 |
F-Score6
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y70.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.35%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y93.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.89%
OCF growth 3YN/A
OCF growth 5YN/A
CRONOS GROUP INC / CRON FAQ
What is the fundamental rating for CRON stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRON.
What is the valuation status for CRON stock?
ChartMill assigns a valuation rating of 1 / 10 to CRONOS GROUP INC (CRON). This can be considered as Overvalued.
How profitable is CRONOS GROUP INC (CRON) stock?
CRONOS GROUP INC (CRON) has a profitability rating of 3 / 10.
What is the expected EPS growth for CRONOS GROUP INC (CRON) stock?
The Earnings per Share (EPS) of CRONOS GROUP INC (CRON) is expected to decline by -115.3% in the next year.